Accelerated suppression of primary EBV infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.

Clinical Infectious Diseases

PubMedID: 24550373

Slyker JA, Casper C, Tapia K, Richardson B, Bunts L, Huang ML, Wamalwa D, Benki-Nugent S, John-Stewart G. Accelerated suppression of primary EBV infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy. Clin Infect Dis. 2014;58(9):1333-7.
We compared primary Epstein-Barr virus (EBV) infection and suppression between Kenyan HIV-infected infants starting nevirapine- versus lopinavir/ritonavir-based antiretroviral regimens. Although the rate of EBV infection was similar between groups, infants receiving lopinavir/ritonavir suppressed EBV more rapidly. Our findings suggest specific antiretrovirals may potentially impact the risk of future EBV-associated malignancies.